Skip survey header

NTCA Provider Guidance: 4-Month HPMZ Regimen for Tuberculosis Publication Registration V1

Thank you for your interest in the NTCA Provider Guidance: A 4-Month Regimen to Treat Pulmonary Tuberculosis: Isoniazid, Rifampin, Moxifloxacin, and Pyrazinamide (HPMZ).

The National Society of TB Clinicians (NSTC) and National TB Nurse Coalition (NTNC) collaborated to develop guidance for providers on using the 4-month regimen of isoniazid, rifampin, moxifloxacin, and pyrazinamide, abbreviated as HPMZ, to treat patients for pulmonary TB disease.

The guidance includes a two-page fact sheet that includes:
  • A description of the length, drugs, and dosages of the HPMZ regimen
  • Photos of medications
  • Advantages and disadvantages of the HPMZ regimen
  • Common drug-drug interactions
  • Possible adverse events
  • Pre-treatment patient checklist
  • Baseline and follow-up monitoring and evaluation
  • Programmatic considerations
For background, more detailed information, and special circumstances, there is an FAQ at that provides background on Study 31 and answers common questions about medications, monitoring, and special patient populations.

This resource is provided at no charge, but we do request that you register your download with your email address so that NTCA can track interest in the publication and alert you when updates are released. 

Please enter your email address below.
This question requires a valid email address.
This question requires a valid email address.